Bristol-Myers Squibb announces post-closing leadership team
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (NASDAQ:CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline,
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
- Details
- Category: Novartis
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1].
Merck pioneers new effort to see MS from the inside out
- Details
- Category: Merck Group
Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of the 2.3 million people worldwide living with this challenging disease. In support of this year’s World MS Day theme, #MyInvisibleMS, Merck is making MS visible through a variety of initiatives aimed at shining a light on the hidden symptoms of MS.
Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma
- Details
- Category: Bayer
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have received at least two prior therapies. MZL is an indolent form of non-Hodgkin's Lymphoma (iNHL) and accounts for about 10% of all non-Hodgkin's Lymphoma in the U.S.
Amgen joins with community oncology networks for new research collaboration
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative oncology clinical research. Fewer than one in 20 adult cancer patients in the U.S. have participated in a clinical trial.
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint. Treatment with LYRICA did not result in a statistically significant reduction in seizure frequency versus placebo.
APRINOIA Therapeutics awarded grant from The Michael J. Fox Foundation for Parkinson's Research
- Details
- Category: Business
APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been awarded are search grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.
More Pharma News ...
- New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
- Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
- Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
- Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today
- Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
- Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program
- Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer